# Insights on Oligometastatic Non-Small-Cell Lung Cancer

## TL;DR

This review discusses oligometastatic non-small-cell lung cancer, a subtype with limited metastases that may benefit from aggressive treatment combining local therapies and systemic approaches.

## Contribution

The paper provides a narrative review of the biological and clinical features of oligometastatic NSCLC and highlights the potential of combining local and systemic therapies.

## Key findings

- Oligometastatic NSCLC is a distinct subtype with limited metastases and a more indolent course.
- Local ablative therapies like surgery and radiotherapy are key treatment options.
- Combining local therapies with immunotherapy or targeted therapy shows promise but requires further refinement.

## Abstract

Non-small-cell lung cancer (NSCLC) is often diagnosed at advanced stages, where treatment options are usually limited. A subgroup of patients presents with only a few metastases, a condition known as oligometastatic NSCLC (OMD-NSCLC). These patients may benefit from more aggressive treatment aimed at long-term control. This review explains how OMD-NSCLC is defined, how it can be identified through imaging and clinical features, and what treatments are available. Local treatments such as surgery or radiotherapy can be used to treat all tumors. New research also explores the biology of the disease, including genetic and molecular markers that may predict better outcomes. The combination of local therapies with immunotherapy or targeted therapy is being explored in clinical trials. Understanding who may benefit most from these strategies is key to improving survival and quality of life in OMD-NSCLC.

Oligometastatic non-small-cell lung cancer (OMD-NSCLC) has emerged as a biologically and clinically distinct subtype of advanced disease, characterized by limited metastatic burden and a more indolent course. In this narrative review, we examine the current definition of OMD-NSCLC, diagnostic tests, possible biomarkers, and current therapeutic strategies. Biological insights highlight the role of microRNAs in differentiating true oligometastatic state from polymetastatic disease. The main local ablative therapies (LAT) include surgery and radiotherapy. The integration of LAT with systemic therapies has been explored in clinical trials, yielding promising but occasionally inconsistent results. As the therapeutic landscape of OMD-NSCLC patients continues to evolve, refining definitions, identifying predictive biomarkers, and individualizing care are essential steps toward achieving the potential of radical-intent therapy.